Royal Bank Of Canada Checkpoint Therapeutics, Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.02 - $10.6 $10,027 - $104,208	-9,831 Reduced 7.21%	126,519 $131,000
Q2 2022 Aug 15, 2022	SELL	$0.97 - $1.77 $90,304 - $164,781	-93,097 Reduced 40.57%	136,350 $140,000
Q1 2022 May 16, 2022	BUY	$1.53 - $3.25 $243,686 - $517,634	159,272 Added 226.96%	229,447 $406,000
Q4 2021 Feb 14, 2022	SELL	$2.68 - $4.46 $107 - $178	-40 Reduced 0.06%	70,175 $218,000
Q3 2021 Nov 15, 2021	BUY	$2.5 - $3.53 $17,247 - $24,353	6,899 Added 10.9%	70,215 $232,000
Q2 2021 Aug 16, 2021	BUY	$2.36 - $3.2 $149,425 - $202,611	63,316 New	63,316 $187,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $351M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.